Keyphrases
Acute Coronary Syndrome
12%
Acute Decompensated Heart Failure
12%
Acute Myocardial Infarction
35%
Adverse Outcomes
6%
All-cause Mortality
10%
Angioplasty
9%
Arrhythmia
9%
Aspirin
7%
Atrial Fibrillation
18%
Beta-blockers
7%
Blood Pressure
10%
Ca2+
10%
Cardiac Function
11%
Cardiac Hypertrophy
6%
Cardiac Resynchronization Therapy
8%
Cardiomyocytes
10%
Cardiomyopathy
8%
Cardiotoxicity
6%
Cardiovascular Disease
30%
Cardiovascular Mortality
9%
Cardiovascular Risk
10%
Chronic Heart Failure
7%
Clinical Outcomes
16%
Clinical Trials
10%
Comorbidity
6%
Confidence Interval
33%
Congestive Heart Failure
13%
Coronary Artery Bypass Grafting
6%
Coronary Artery Disease
25%
COVID-19
8%
Diabetes
10%
Diastolic Filling
8%
Diastolic Function
11%
Dilated Cardiomyopathy
7%
E Wave
8%
Echocardiographic
14%
Echocardiography
12%
Ejection Fraction
11%
Elderly Patients
6%
Flow Velocity
6%
Gene Expression
7%
Hazard Ratio
17%
Heart Failure
83%
Heart Failure Hospitalization
6%
Heart Failure Patients
12%
Heart Failure with Preserved Ejection Fraction (HFpEF)
20%
Heart Rate
11%
Heart Rate Variability
15%
Heart Transplantation
6%
High Risk
13%
Hospitalization
11%
Hypertension
16%
In-hospital Mortality
7%
India
6%
Infarction
8%
Inflammation
9%
Ischemia
6%
Left Ventricle
7%
Left Ventricular Assist Device
11%
Left Ventricular Dysfunction
11%
Left Ventricular Ejection Fraction
15%
Left Ventricular End-diastolic Pressure
6%
Left Ventricular Function
35%
Left Ventricular Remodeling
6%
Macrophages
13%
Magnetic Resonance Imaging
8%
Medicare
9%
Medicare Beneficiaries
7%
Meta-analysis
11%
Molecular Imaging
12%
Mouse Model
6%
Myocardial Infarction
35%
Myocardium
17%
Myocytes
12%
Nanoparticles
11%
National Cardiovascular Data Registry
7%
Obesity
7%
Odds Ratio
13%
Older Adults
16%
Older Patients
7%
Overexpression
6%
Pathophysiology
6%
Patients with Coronary Artery Disease
6%
Patients with Heart Failure
25%
Percutaneous Coronary Intervention
27%
Perfluorocarbon Nanoparticles
10%
Placebo
8%
Quality of Life
8%
Randomized Clinical Trial
7%
Randomized Controlled Trial
7%
Readmission
7%
Revascularization
10%
Risk Factors
12%
ST-elevation Myocardial Infarction (STEMI)
6%
Transcatheter Aortic Valve Replacement
9%
Tumor Necrosis Factor-α
13%
Type 1 Diabetes Mellitus (T1DM)
7%
Type 2 Diabetes Mellitus (T2DM)
7%
United States
14%
Ventricular Arrhythmia
9%
Medicine and Dentistry
Acute Coronary Syndrome
8%
Acute Decompensated Heart Failure
5%
Acute Heart Infarction
22%
Adverse Event
6%
Angiography
6%
Angioplasty
9%
Aortic Dissection
6%
Aortic Stenosis
6%
Apoplexy
19%
Assisted Circulation
6%
Atherosclerosis
9%
Atrial Fibrillation
16%
Biological Marker
8%
Bleeding
6%
Blood Pressure
10%
Calcium Ion
6%
Cardiac Catheterization
7%
Cardiac Dysrhythmia
7%
Cardiac Muscle Cell
11%
Cardiac Resynchronization Therapy
9%
Cardiology
10%
Cardiotoxicity
5%
Cardiovascular Disease
34%
Cardiovascular Risk
6%
Cardiovascular System
47%
Clinical Trial
10%
Clinician
7%
Combination Therapy
9%
Comorbidity
7%
Congestive Heart Failure
100%
Contrast Medium
6%
Coronary Angiography
6%
Coronary Artery
6%
Coronary Artery Bypass Graft
6%
Coronary Artery Disease
23%
COVID-19
8%
Diabetes
14%
Diabetes Mellitus
10%
Diagnosis
11%
Diastolic Function
12%
Dilated Cardiomyopathy
6%
Diseases
27%
Echocardiography
19%
Ejection Fraction
15%
Electrocardiogram
8%
Exercise
6%
Fluorocarbon
6%
Hazard Ratio
13%
Health Care Cost
12%
Heart Disease
10%
Heart Failure with Preserved Ejection Fraction
7%
Heart Function
8%
Heart Graft
6%
Heart Left Ventricle Ejection Fraction
11%
Heart Left Ventricle Failure
7%
Heart Left Ventricle Function
7%
Heart Muscle Ischemia
8%
Heart Rate Variability
9%
Heart Transplantation
9%
Heart Ventricle Remodeling
9%
Hemodynamic
14%
Hospital Mortality
6%
Infarction
10%
Infection
5%
Ischemia
5%
Ischemic Heart Disease
11%
Left Ventricle
6%
Left Ventricular Assist Device
14%
Lung
5%
Macrophage
8%
Magnetic Resonance Imaging
9%
Malignant Neoplasm
8%
Medicare
19%
Meta-Analysis
8%
Molecular Imaging
10%
Mortality Rate
7%
Myocardial Disease
10%
Myocardial Infarction
28%
Myocardium
13%
Nanoparticle
13%
Odds Ratio
15%
Oncology
5%
Outpatient
7%
Percutaneous Aortic Valve Replacement
10%
Percutaneous Coronary Intervention
24%
Placebo
6%
Prevalence
11%
Quality of Life
10%
Randomized Controlled Trial
7%
Revascularization
11%
Surgery
6%
Systematic Review
5%
Systolic Blood Pressure
6%
Systolic Function
7%
Transluminal Coronary Angioplasty
6%
Tumor Necrosis Factor
7%
Ventricular Assist Device
5%
Ventricular Hypertrophy
6%
Ventricular Tachycardia
5%
Veterans Affairs
6%